daclizumab(redirected from Dacliximab)
an immunosuppressant used to prevent acute organ rejection in renal transplant patients; administered intravenously.
daclizumab/da·cliz·u·mab/ (dah-kliz´u-mab) an immunosuppressant used to prevent acute organ rejection in renal transplant patients.
indications It is used to help prevent acute allograft rejection in renal transplant patients.
contraindications Known hypersensitivity to this drug contraindicates its use.
adverse effects Life-threatening effects are pulmonary edema, tachycardia, thrombosis, renal tubular necrosis, and hydronephrosis. Other adverse effects include headache, prickly sensation, coughing, atelectasis, congestion, constipation, abdominal pain, pyrosis, hypertension, bleeding, oliguria, dysuria, renal damage, and impaired wound healing. Common side effects include chills, tremors, dyspnea, wheezing, vomiting, nausea, and diarrhea.